The Beginning of a New Era for the Treatment of HCV
Douglas T. Dieterich, MD
Professor of Medicine, Division of Liver Diseases,
Director of Outpatient Hepatology,
Icahn School of Medicine at Mount Sinai, New York, NY
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2013. All rights reserved.
Doug Dieterich is currently Professor of Medicine in the Division of Hepatology, with a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases at the Icahn School of Medicine at Mount Sinai in New York City. He is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic hepatitis B & C. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis. Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS associated infections of the gastrointestinal tract and liver.
At the completion of this educational session, learners will:
- Appreciate the history of HCV treatment with and without HIV coinfection.
- Understand the use of directly acting agents (DAAs) for HCV.
- Be aware of the new all-oral combinations for HCV treatment.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences, Janssen Therapeutics, and Merck & Co.
